FDA Antimicrobial Development Draft Guidances Withdrawn Under Rejuvenation Initiative
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA says the 13 guidances are out of date and of no use to industry; a number of others covering various topics also will be revised or finalized.
You may also be interested in...
Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding
FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.
COVID-19 Vaccine Distribution Confusion Grows As Eligibility Widens
President-Elect Biden also adds David Kessler and Andy Slavitt to his COVID-19 response team, retains Francis Collins at NIH director.
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: